Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Frevecitinib in airway epithelial cells from severe asthma
NCT02740049Phase 1Completed
- Sponsor
- Imperial College London
- Start
- Jan 2016
- Primary completion
- Oct 2016
- Modality
- Inhalation Devices, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of frevecitinib in asthma, sponsored by Imperial College London. Primary endpoints: Concentration of CXCL8 Cytokine in Cell Supernatant at 21 days, Percentage of Viable Cells Compared to Baseline at 21 days and 1 more. Started Jan 2016; status: completed.
02
Drugs
frevecitinib
03
Conditions
asthma
Beyond the preview
Go deeper on NCT02740049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02740049.